Schechter Investment Advisors LLC Sells 1,434 Shares of ICON Public Limited (NASDAQ:ICLR)

Schechter Investment Advisors LLC decreased its stake in ICON Public Limited (NASDAQ:ICLR) by 47.4% in the fourth quarter, Holdings Channel.com reports. The firm owned 1,593 shares of the medical research company’s stock after selling 1,434 shares during the period. Schechter Investment Advisors LLC’s holdings in ICON Public were worth $334,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the stock. Kornitzer Capital Management Inc. KS boosted its stake in ICON Public by 40.6% during the fourth quarter. Kornitzer Capital Management Inc. KS now owns 97,102 shares of the medical research company’s stock worth $20,363,000 after buying an additional 28,050 shares during the period. Foyston Gordon & Payne Inc bought a new stake in shares of ICON Public in the 3rd quarter worth about $11,672,000. Icon Wealth Advisors LLC lifted its holdings in shares of ICON Public by 861.1% in the 3rd quarter. Icon Wealth Advisors LLC now owns 13,215 shares of the medical research company’s stock worth $3,797,000 after acquiring an additional 11,840 shares during the last quarter. Entropy Technologies LP boosted its stake in shares of ICON Public by 472.2% during the 4th quarter. Entropy Technologies LP now owns 6,174 shares of the medical research company’s stock worth $1,295,000 after purchasing an additional 5,095 shares during the period. Finally, Tributary Capital Management LLC grew its holdings in ICON Public by 116.1% during the 4th quarter. Tributary Capital Management LLC now owns 3,950 shares of the medical research company’s stock valued at $828,000 after purchasing an additional 2,122 shares during the last quarter. Institutional investors own 95.61% of the company’s stock.

ICON Public Trading Up 1.6 %

NASDAQ:ICLR opened at $186.49 on Thursday. The firm has a 50-day simple moving average of $200.78 and a 200-day simple moving average of $238.28. ICON Public Limited has a one year low of $179.50 and a one year high of $347.72. The firm has a market cap of $15.06 billion, a P/E ratio of 19.57, a P/E/G ratio of 1.86 and a beta of 1.21. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.34 and a current ratio of 1.26.

ICON Public (NASDAQ:ICLR) last issued its quarterly earnings data on Wednesday, February 19th. The medical research company reported $3.42 EPS for the quarter, topping analysts’ consensus estimates of $3.41 by $0.01. The company had revenue of $2.04 billion during the quarter, compared to the consensus estimate of $2.04 billion. ICON Public had a net margin of 9.56% and a return on equity of 11.81%. Equities analysts anticipate that ICON Public Limited will post 13.38 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have issued reports on ICLR. JPMorgan Chase & Co. decreased their price objective on shares of ICON Public from $280.00 to $265.00 and set an “overweight” rating for the company in a research note on Monday, February 3rd. William Blair reissued an “outperform” rating on shares of ICON Public in a research note on Tuesday, January 14th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $263.00 price objective on shares of ICON Public in a research report on Wednesday, January 15th. Citigroup decreased their target price on ICON Public from $300.00 to $290.00 and set a “buy” rating for the company in a research report on Monday, January 6th. Finally, Truist Financial lowered their target price on shares of ICON Public from $284.00 to $262.00 and set a “buy” rating for the company in a research note on Thursday, February 13th. Four research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $279.17.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.